Brandi K Fulgham, MCP, LPC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 405 S Oklahoma Ave, Cherokee, OK 73728 Phone: 580-596-2800 |
News Archive
Mount Sinai School of Medicine has completed an exclusive option agreement with Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, for intellectual property related to RNAi applications in vaccine development. These new applications of RNAi technology define opportunities for the advancement of novel vaccines in infectious disease.
People with persistent back pain or persistent headaches are twice as likely to suffer from both disorders, a new study from the University of Warwick has revealed.
HIV is coated in sugars that usually hide the virus from the immune system. Newly published research reveals how one broadly neutralizing HIV antibody actually uses part of the sugary cloak to help bind to the virus. The antibody binding site, called the V1/V2 region, represents a suitable HIV vaccine target, according to the scientists who conducted the study. In addition, their research reveals the detailed structure of the V1/V2 region, the last part of the virus surface to be visualized at the atomic level.
Mayo Clinic researchers have discovered that the five-year survival of diabetic kidney transplant patients is now on par with the five-year survival of nondiabetic kidney recipients.
› Verified 5 days ago